MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

REVOLUTION Medicines Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

38.3 -1.85

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

38.2

Max

39.06

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-19M

-213M

Pelnas, tenkantis vienai akcijai

-1.13

Pelno marža

-74.379

Darbuotojai

616

EBITDA

-24M

-237M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+79.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-437M

7.1B

Ankstesnė atidarymo kaina

40.15

Ankstesnė uždarymo kaina

38.3

Naujienos nuotaikos

By Acuity

61%

39%

319 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-18 21:01; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 20:46; UTC

Uždarbis

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025-07-18 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 20:36; UTC

Uždarbis

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025-07-18 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025-07-18 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 20:02; UTC

Rinkos pokalbiai

Gold Higher to Close Out Week -- Market Talk

2025-07-18 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025-07-18 19:06; UTC

Rinkos pokalbiai

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025-07-18 18:24; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025-07-18 18:19; UTC

Uždarbis

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025-07-18 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025-07-18 18:11; UTC

Uždarbis

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025-07-18 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025-07-18 16:29; UTC

Rinkos pokalbiai

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025-07-18 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 16:04; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025-07-18 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-18 15:58; UTC

Rinkos pokalbiai

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025-07-18 15:47; UTC

Rinkos pokalbiai
Uždarbis

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Akcijų palyginimas

Kainos pokytis

REVOLUTION Medicines Inc Prognozė

Kainos tikslas

By TipRanks

79.82% į viršų

12 mėnesių prognozė

Vidutinis 70.22 USD  79.82%

Aukščiausias 80 USD

Žemiausias 57 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines REVOLUTION Medicines Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

10

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

40.67 / 41.96Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

319 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.